Knight Therapeutics | GUD - Cash And Equivalent


Knight Therapeutics reported CAD76.45M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acasti Pharma USD 18.67M 1.81M Dec/2025
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Canopy Growth CAD 364.68M 6.64M Mar/2026
Cronos Group USD 467.02M 354.84M Jun/2026
Dianthus Therapeutics USD 110.55M 517.12M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Moderna USD 1.72B 185M Jun/2026
Omeros USD 1.9M 2.36M Jun/2025
Organigram Holdings CAD 4.29M 3.28M Mar/2026
Organon & Co USD 1.13B 16M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Tilray USD 264.83M 43.16M Jun/2025
Viatris USD 886.5M 917.7M Jun/2026
Xeris Pharmaceuticals USD 121.75M 10M Jun/2026